Skip to content
OpenCapital
Get started

Bio-Rad Laboratories, Inc. BIO.B Sale of investments

Sale of investments at other companies

TEC
Bio-TechneTECH
——

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×—
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s sale of investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s sale of investments?
Bio-Rad Laboratories, Inc. (BIO.B) reported sale of investments of $145.1M in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s sale of investments changed year-over-year?
Bio-Rad Laboratories, Inc.'s sale of investments decreased by 15.2% year-over-year, from $171.2M to $145.1M.
What is the long-term trend for Bio-Rad Laboratories, Inc.'s sale of investments?
Over 4 years (2021 to 2025), Bio-Rad Laboratories, Inc.'s sale of investments has grown at a 16.9% compound annual growth rate (CAGR), from $425.54M to $793.6M.
What does sale of investments mean?
This represents cash inflows from the sale of marketable securities, such as corporate bonds or government debt, classified as available-for-sale. It reflects the company's active management of its liquid investment portfolio.